azaCITIDine (Oral) Monotherapy
Regimen
|
00818a
Maintenance treatment in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation (HSCT).
|
azaCITIDine75mg/m2 5-2-2 Therapy
Regimen
|
00287d
Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to WHO classification.
|
azaCITIDine 100mg/m2 5-day Therapy
Regimen
|
00288d
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to WHO classification.
|
Intermediate Dose Cytarabine Therapy
Regimen
|
00364a
Consolidation chemotherapy for the treatment of patients Acute Myeloid Leukaemia (AML)
|
High Dose Cytarabine Therapy
Regimen
|
00365a
Consolidation chemotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML)
|
DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)
Regimen
|
00359a
Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)
|
DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)
Regimen
|
00360a
Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)
|
Decitabine Monotherapy – AML (28 day cycle)
Regimen
|
00231a
Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy.
|
FLAG Therapy
Regimen
|
00363a
Treatment of Acute Myeloid Leukaemia (AML) in patients unsuitable for treatment with idarubicin or as consolidation post FLAG-Ida.
00363c
Salvage regimen for patients with relapsed/refractory acute leukaemia.
|
FLAG: Ida 8mg/m2 Therapy
Regimen
|
00362a
Induction of chemotherapy regimen for the treatment of patients with de novo, secondary Acute Myeloid Leukaemia (AML), or biphenotypic leukaemia.
00362c
Salvage regimen for patients with relapsed/refractory acute leukaemia
|
Gemtuzumab Ozogamicin, DAUNOrubicin and Cytarabine Therapy (AML induction)
Regimen
|
00612a
Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukaemia (AML), except acute promyeloytic leukaemia
|
Midostaurin Maintenance Therapy
Regimen
|
00661a
Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy
|
Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy
Regimen
|
00682a
Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive
|
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy
Regimen
|
00683a
Midostaurin is indicated in combination with intermediate dose cytarabine consolidation consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.
|
Vyxeos liposomal® DAUNOrubicin and Cytarabine Induction Therapy
Regimen
|
00613a
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
|
Vyxeos liposomal® DAUNOrubicin and Cytarabine Consolidation Therapy
Regimen
|
00618a
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
|
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy
Regimen
|
00356a
Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC count ≤ 10x109 /L)
00356b
Treatment of adult patients with relapsed or refractory APL after ATRA/chemotherapy.
|
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy
Regimen
|
00357a
Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356).
|
Tretinoin (ATRA)IDArubicin (PETHEMA AIDA) Induction Therapy:High Risk
Regimen
|
00366a
Treatment of patients with newly diagnosed high risk Acute Promyelocytic Leukaemia (APL)
|
Blinatumomab Therapy
Regimen
|
00538a
Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).
|
Blinatumomab Therapy (ALL with MRD ≥ 0.1%)
Regimen
|
00590a
As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
|
Inotuzumab ozogamicin Monotherapy
Regimen
|
00537a
Monotherapy for the treatment of adults with relapsed or refractory CD22- positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).
|
PONATinib Therapy
Regimen
|
00302a
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
|
Venetoclax and azaCITIDine Therapy
Regimen
|
00852a
Venetoclax in combination with azaCITIDine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy
|